Literature DB >> 16226395

Relapse patterns in WHO 2/3 nasopharyngeal cancer: is there a difference between ethnic Asian vs. non-Asian patients?

June Corry1, Richard Fisher, Danny Rischin, Lester J Peters.   

Abstract

PURPOSE: The purpose of this study was to assess whether ethnicity is an independent prognostic factor in patients with World Health Organization (WHO) type 2 or 3 nasopharyngeal carcinoma (NPC). Specifically, we examined the patterns of relapse observed in patients classified as "Asian" (born in southern China or southeast Asia) or "non-Asian" (born in Australia, Europe, the Middle East, or the Pacific Islands). METHODS AND MATERIALS: All patients planned for radical treatment at the Peter MacCallum Cancer Centre from April 1985 to December 1999 were included in this study. Pathology was reviewed to confirm WHO type 2 or 3 NPC. Patients were staged using the 1997 International Union Against Cancer (UICC) criteria. Mean potential follow-up time was 9.6 years (range, 1.0-18.5 years)
RESULTS: There were 158 patients: 86 Asian and 72 non-Asian. Stage groupings were: I--12 patients; II--32 patients; III--59 patients; and IV--55 patients. A staging computerized tomography was performed in 121 patients, and 53 (34%) also had a staging magnetic resonance imaging (MRI). The Asian patients had significantly more women, more patients aged <45, and more with performance status 0 than the non-Asians. Other putative prognostic factors were not significantly different between the groups. The 5-year rates for freedom from local recurrence (FLR), failure-free survival (FFS), and overall survival (OS) for Asian and non-Asian patients were 74% vs. 82%, 61% vs. 55%, and 75% vs. 63%, respectively. Corresponding 10-year figures were: 62% vs. 82%, 43% vs. 48%, and 58% vs. 49%, respectively. Multifactor analysis showed stage and the use of MRI for staging to be significant prognostic factors for all three endpoints. Age was also significant for FFS and OS. There were no significant differences in FFS or OS between Asian and non-Asian patients. However, the FLR interval was significantly worse in the Asian group (hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.11-5.06), whereas duration of freedom from distant metastasis tended to be better (HR, 0.71; 95% CI, 0.33-1.53).
CONCLUSIONS: Although this study provides no evidence that race is an independent prognostic factor for overall survival in patients with WHO 2/3 NPC, it does suggest that relapse patterns may vary, with a higher rate of late primary failures (offset by a lower rate of distant failure) in the Asian population. Further confirmatory studies with larger patient cohorts are indicated.

Entities:  

Mesh:

Year:  2005        PMID: 16226395     DOI: 10.1016/j.ijrobp.2005.06.041

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part I: Evolving technical choices and survival.

Authors:  S Tonoli; S M Magrini; L Costa; F Paiar; G Simontacchi; V Scotti; N Pasinetti; R Barca; D Barbieri; A De Stefani; E Cellai; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

2.  A nonendemic analysis of the patterns and prognosis of de novo metastatic nasopharyngeal carcinomas in older patients aged ≥ 65 years.

Authors:  Baoqiu Liu; Mingxing Zhang; Yanqing Cao; Zhe Wang; Xicheng Wang
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

3.  MR imaging prediction of local control of nasopharyngeal carcinoma treated with radiation therapy and chemotherapy.

Authors:  Y Wang; H Zhao; Z-Q Zhang; L-L Huang; Y Ye; Y-B Wang; M-J Han
Journal:  Br J Radiol       Date:  2014-05-14       Impact factor: 3.039

4.  Accuracy of a Staging System for Prognosis of 5-Year Survival of Patients With Nasopharyngeal Carcinoma Who Underwent Chemoradiotherapy.

Authors:  Chung-I Huang; Li-Fu Chen; Shih-Lun Chang; Hung-Chang Wu; Wei-Chen Ting; Ching-Chieh Yang
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

5.  Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview.

Authors:  David C Whiteman; Penelope M Webb; Adele C Green; Rachel E Neale; Lin Fritschi; Christopher J Bain; D Max Parkin; Louise F Wilson; Catherine M Olsen; Christina M Nagle; Nirmala Pandeya; Susan J Jordan; Annika Antonsson; Bradley J Kendall; Maria Celia B Hughes; Torukiri I Ibiebele; Kyoko Miura; Susan Peters; Renee N Carey
Journal:  Aust N Z J Public Health       Date:  2015-10       Impact factor: 2.939

6.  Cancers in Australia in 2010 attributable to infectious agents.

Authors:  Annika Antonsson; Louise F Wilson; Bradley J Kendall; Christopher J Bain; David C Whiteman; Rachel E Neale
Journal:  Aust N Z J Public Health       Date:  2015-10       Impact factor: 2.939

7.  Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy.

Authors:  Y-M Tian; Y-H Tian; L Zeng; S Liu; Y Guan; T-X Lu; F Han
Journal:  Br J Cancer       Date:  2013-12-12       Impact factor: 7.640

8.  Palliative chemotherapy in carcinoma nasopharynx.

Authors:  Vijay M Patil; Amit Joshi; Vanita Noronha; Vikas Talreja; Vijai Simha; Sachin Dhumal; Bhavesh Bandekar; Arun Chandrasekharan; Kumar Prabhash
Journal:  South Asian J Cancer       Date:  2019 Jul-Sep

9.  S100A8/A9 Molecular Complexes Promote Cancer Migration and Invasion via the p38 MAPK Pathway in Nasopharyngeal Carcinoma.

Authors:  Ning Xu; Bei-Bei Zhang; Xia-Ning Huang; Xiang Yi; Xue-Min Yan; Yan Cai; Qin He; Zi-Jian Han; Yuan-Jiao Huang; Wei Liu; Ai-Jun Jiao
Journal:  Bioinorg Chem Appl       Date:  2021-06-22       Impact factor: 7.778

10.  Effectiveness and toxicities of intensity-modulated radiotherapy for patients with locally recurrent nasopharyngeal carcinoma.

Authors:  Hai-yan Chen; Xiu-mei Ma; Ming Ye; Yan-li Hou; Hua-Ying Xie; Yong-rui Bai
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.